Here are the top stories from the last week:
Industry Updates
NACDS Urges Federal Agencies to Include Pharmacies in Health Data Infrastructure
The article discusses NACDS’ call to action for federal agencies to include pharmacies in the health data infrastructure as part of efforts to modernize the U.S. healthcare technology ecosystem. Read article »
Lumeris Partners with Google Cloud to Address U.S. Primary Care Shortage
Lumeris and Google Cloud have partnered to improve access to primary care in the U.S. by building Lumeris’ Tom platform on Google Cloud technology, aiming to expand capacity and reduce administrative burdens in primary care. Read article »
Mallinckrodt, Endo Announce Leadership for Merged Company
Mallinckrodt and Endo announced the leadership team for their merged company, Par Health, which will focus on branded specialty pharmaceuticals and generics. Read article »
NACDS Applauds Senate Action on PBM Reforms, Joining House in Bipartisan Push
The article covers NACDS’ support for Senate action on PBM reforms, which aim for full transparency from PBMs, including the pass-through of ingredient costs and pharmacy dispensing fees. Read article »
CVS Media Exchange, Reddit Form Health, Wellness, Beauty Partnership
CVS Media Exchange is collaborating with Reddit to offer brands new ways to reach consumers seeking health, wellness, and beauty products, leveraging first-party loyalty data and Reddit’s user engagement. Read article »
Walgreens, Kourtney Kardashian Reportedly Looking at Rite Aid Assets
Walgreens and Kourtney Kardashian are among those interested in acquiring Rite Aid’s assets, including its Thrifty ice cream brand. Read article »
PCMA Backs Bipartisan Push to Eliminate Biosimilar Red Tape
This article reports on PCMA’s support for a bipartisan measure to eliminate red tape around biosimilars, which is seen as a step towards increasing market competition and reducing drug costs. Read article »
Drug, Technology & Treatment Updates
Azurity Pharmaceuticals Obtains FDA OK for Xifyrm
Azurity Pharmaceuticals received FDA approval for Xifyrm, an IV non-steroidal anti-inflammatory drug for managing moderate-to-severe pain, providing a non-opioid analgesic option. Read article »
Alvotech, Dr. Reddy’s to Co-Develop Keytruda Biosimilar
Alvotech and Dr. Reddy’s have partnered to co-develop a biosimilar to Keytruda, aiming to expand global access to this cancer treatment. Read article »
Samsung Bioepis Partners with NIPRO for Multiple Biosimilars in Japan
The two companies will develop and commercialize multiple biosimilars in Japan, enhancing treatment options in therapeutic areas like immunology. Read article »